Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cumulative Dose Tolerability of Levalbuterol HFA vs Racemic Albuterol HFA in Asthma
NCT00684827Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of levalbuterol in asthma (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Heart Rate at Day 10, Blood Pressure (Systolic and Diastolic) at Day 10 and 2 more. Started Oct 2002; status: completed.
02
Drugs
levalbuterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00684827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00684827.